Search
Lung Cancer
S1800E
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
EAY191-N5 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors. A ComboMATCH Treatment Trial
A172401 (WF2304-A172401)
Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
EAY191-E5 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
S1900K (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
EAY191-S3 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
Molecular Analysis for Combination Therapy Choice (ComboMATCH): Protocol EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors
A082304 (CTIU2317-A082304-S2402)
Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer – PROSPECT LUNG
SWOG S1900J
A Phase II Study of Amivantamab in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
AFT-57
Randomized phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoimmunotherapy for unresectable stage III NSCLC
URCC 19185
Multicenter Randomized Controlled Trial comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
